Physician profile
Brian Harner
NPI 1780011122
$10,470.45
in general payments reported to CMS, 2019-2025
32 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $2,110 · 2023: $1,907 · 2024: $2,769 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,679 · Education: $95.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,679.26 |
| Education | $95.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,150.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,193.78 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,128.73 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $675.51 | 2021-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $385.26 | 2021-2025 | Linzess |
| Ardelyx, INC. | $369.35 | 2022-2025 | Ibsrela |
| Pfizer INC. | $358.19 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $293.37 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $272.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $234.99 | 2021-2022 | |
| Daiichi Sankyo INC. | $176.59 | 2021-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $143.34 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $138.14 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $132.88 | 2021 | |
| Gilead Sciences, INC. | $123.95 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $92.21 | 2024-2025 | Omvoh |
| Evoke Pharma, INC. | $76.41 | 2021-2023 | Gimoti |
| Janssen Pharmaceuticals, INC | $75.44 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $71.26 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $62.18 | 2022-2024 | Suflave |
| Amgen INC. | $51.49 | 2021-2023 | Amjevita, Avsola |
| Novo Nordisk INC | $43.47 | 2025 | Wegovy |
| Genzyme Corporation | $37.67 | 2022-2023 | |
| Henry Schein, INC. | $32.72 | 2023 | |
| Nestle Healthcare Nutrition INC. | $30.16 | 2021-2023 | |
| Laborie Medical Technologies Corp. | $22.81 | 2025 | |
| Medtronic, INC. | $20.81 | 2024 | Interstim |
| Avanir Pharmaceuticals, INC. | $20.74 | 2021 | |
| Fresenius Kabi USA, LLC | $19.94 | 2024 | Idacio |
| Endogastric Solutions, INC | $13.34 | 2024 | Esophyx |
| Alfasigma USA, INC. | $12.67 | 2022 | |
| Ambu INC. | $10.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Harner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.